Your browser doesn't support javascript.
loading
Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia.
Adam, Makka; Bekueretsion, Yonas; Abubeker, Abdulaziz; Tadesse, Fisihatsion; Kwiecinska, Anna; Howe, Rawleigh; Petros, Beyene; Jerkeman, Mats; Gebremedhin, Amha.
Afiliação
  • Adam M; Department of Microbial, Cellular and Molecular Biology, College of Natural Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Bekueretsion Y; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Abubeker A; Department of Oncology, Faculty of Medicine, Lund University, Lund, Sweden.
  • Tadesse F; Yirgalem Medical College, Yirgalem, Ethiopia.
  • Kwiecinska A; Department of Pathology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Howe R; Department of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Petros B; Department of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Jerkeman M; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
  • Gebremedhin A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
JCO Glob Oncol ; 7: 277-288, 2021 02.
Article em En | MEDLINE | ID: mdl-33591838
ABSTRACT

PURPOSE:

In developing countries, Hodgkin lymphoma (HL) affects the young population. In Ethiopia, nearly 70% of the population are < 35 years of age. Therefore, this study aimed to elucidate the age distribution, histopathologic patterns, clinical characteristics and treatment outcomes of HL in Ethiopia. MATERIALS AND

METHODS:

Data from clinical records of 133 consecutive patients with HL between 2014 and 2019 were reviewed and collected. Formalin-fixed paraffin-embedded tissue blocks of HL cases were collected and used for subtype classification.

RESULTS:

A total of 68.4% (91) of the patients were male; male-to-female ratio was 2.21. The median age was 22 years. The age distribution was 57.1% (76), 30.8% (41), and 2.3% (3) for the age groups (10-29), (30-59), and (60-69) years, respectively. Thirteen percent (12) were associated with HIV. The majority of the cases, 50.4% (67), were of the mixed-cellularity (MCCHL) subtypes and 30% (40) nodular-sclerosis (NSCCHL). Most HIV-associated cases (60%, 6) were of the MCHL subtype. The 4-year overall survival (OS) was 83.1%. The 4-year OS of early-stage patients was 100% and advanced-stage patients with low-risk (International Prognostic Score [IPS] ≤ 2) and high-risk (IPS ≥ 3) were 94.1% and 62.9%, respectively. All patients who received combined-therapy survived, whereas those who received doxorubicin, bleomycin, vinblastine, and dacarbazine only showed a 4-year OS rate of 77.9%.

CONCLUSION:

HL affects the youngest and most productive population in Ethiopia. The treatment outcome is favorable in both HIV-associated and non-HIV-associated HL. However, the study population was likely a highly selected group as the majority of the Ethiopian population do not have access to specialized care.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: JCO Glob Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Etiópia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: JCO Glob Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Etiópia